These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6385263)

  • 41. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
    Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
    Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mitoxantrone (novantrone): a review of experimental and early clinical studies.
    Smith IE
    Cancer Treat Rev; 1983 Jun; 10(2):103-15. PubMed ID: 6347376
    [No Abstract]   [Full Text] [Related]  

  • 43. [A case of refractory acute lymphocytic leukemia who achieved a complete remission by mitoxantrone].
    Yoshikawa H; Sao H; Tahara T; Akao Y; Yoshikawa S
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):515-20. PubMed ID: 6584088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical pharmacology of mitoxantrone].
    Robak T; Drzewoski J
    Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1473-5. PubMed ID: 3913945
    [No Abstract]   [Full Text] [Related]  

  • 45. Mitoxantrone in malignant lymphoma.
    Gams RA; Steinberg J; Posner L
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):47-9. PubMed ID: 6484580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biologic and biochemical effects of mitoxantrone.
    Durr FE
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):3-10. PubMed ID: 6484579
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience.
    Specchia G; Pastore D; Carluccio P; Spinosa G; Giannoccaro M; Rizzi R; Mestice A; Liso V
    Ann Hematol; 2007 Jun; 86(6):425-8. PubMed ID: 17364181
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
    Kimura I; Ohnoshi T; Hiraki S; Ueoka H; Toyata K; Miyamoto H; Yamane T; Ueno K; Murashima M
    Gan No Rinsho; 1985 May; 31(6 Suppl):767-73. PubMed ID: 4040985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
    Thomas X; Elhamri M; Chelghoum Y; Reman O; Arnaud P; Raffoux E; Le QH; Tavernier E; Dombret H; Michallet M
    Ann Hematol; 2005 Jun; 84(6):376-82. PubMed ID: 15782343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Comparison of the effectiveness of idarubicin (Zavedos) and mitoxantrone (Refador) in induction therapy of acute myeloid leukemia in elderly patients (55-75) (a prospective multicenter randomized study conducted 1998-2000].
    Indrák K; Hubácek J; Mayer J; Voglová J; Jarosová M; Krahulová M; Malý J; Faber E; Penka M; Kmonícek M; Jebavý L; Szotkowski T; Knotková R; Hlusí A; Zapletalová J
    Vnitr Lek; 2001 Sep; 47 Suppl 1():48-56. PubMed ID: 11693063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia.
    Solary E; Caillot D; Chauffert B; Casasnovas RO; Dumas M; Maynadie M; Guy H
    J Clin Oncol; 1992 Nov; 10(11):1730-6. PubMed ID: 1357108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amsacrine in refractory acute leukemia.
    Griffin JD; Maguire ME; Mayer RJ
    Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
    Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
    J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of mitoxantrone and doxorubicin in breast cancer.
    Neidhart JA; Gochnour D; Roach R; Hoth D; Young D
    J Clin Oncol; 1986 May; 4(5):672-7. PubMed ID: 3517241
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical safety and tolerance of mitoxantrone.
    Crossley RJ
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):54-8. PubMed ID: 6385266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mitoxantrone: a promising new chemotherapeutic agent.
    Dalton WS; Alberts DS
    Ariz Med; 1984 Feb; 41(2):96-8. PubMed ID: 6703919
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia.
    Warrell RP; Arlin ZA; Gee TS; Chou TC; Roberts J; Young CW
    Cancer Treat Rep; 1982 Jul; 66(7):1479-85. PubMed ID: 7046929
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
    Bow EJ; Sutherland JA; Kilpatrick MG; Williams GJ; Clinch JJ; Shore TB; Rubinger M; Schacter BA
    J Clin Oncol; 1996 Apr; 14(4):1345-52. PubMed ID: 8648393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.